TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Growth Hormone Co-treatment With the Microflare Stimulation Protocol in IVF/ICSI, Can it be a New Hope for Poor Responders?
Brief Summary: The effect of use of the microflare down regulation protocol on the outcome of the IVF/ICSI cycles in poor responders


Options:
A: Inclusion Criteria:

* females fulfilling the criteria of the ESHRE consensus 2011:
* at least two of the following three features must be present:
* dvanced maternal age (≥40 years) or any other risk factor for POR
* previous POR (≤3 oocytes with a conventional stimulation protocol)
* an abnormal ovarian reserve test (i.e. AFC ,5-7 follicles or AMH ,0.5 -1.1 ng/ml).

Exclusion Criteria:

* women who suffer from any other cause of infertility other than poor ovarian reserve
* refusal of the patient to consent for using her data in the study.
B: Inclusion Criteria:

ESHRE consensus 2011,At least two of the following three features must be present:

* Advanced maternal age (≥40 years) or any other risk factor for POR;
* A previous POR (≤3 oocytes with a conventional stimulation protocol);
* An abnormal ovarian reserve test (i.e. AFC \< 5-7 follicles or AMH \< 0.5 -1.1 ng/ml).

Exclusion Criteria:

* female patients with causes of infertility other than poor ovarian reserve
* females suffering from congenital or acquired uterine anomalies
* females with focal uterine lesions
* females who had previous ovarian surgeries
* females with history of previous exposure to radiotherapy , or chemotherapy
* females refusing to get enrolled in the study
C: Inclusion Criteria:

* Poor responder females are those who posses two out of these three criteria:
* Female age ≥40 years
* Females who have at least one previous cancelled IVF cycle
* POR according to AFC ≤ 5 or low AMH value.

Exclusion Criteria:

* Females over 45 years
* Females with FSH more than 20 IU/l
* Females with previous ovarian surgery
* Females suffering from causes of infertility other than poor ovarian response
* Females refusing to be enrolled in the study
D: Inclusion Criteria:

* females fulfilling the criteria of the ESHRE consensus 2011:

At least two of the following three features must be present:

(i) Advanced maternal age (≥40 years) or any other risk factor for POR; (ii) A previous POR (≤3 oocytes with a conventional stimulation protocol); (iii) An abnormal ovarian reserve test (i.e. AFC ,5-7 follicles or AMH ,0.5 -1.1 ng/ml).

Exclusion Criteria:

* women who suffer from any other cause of infertility other than poor ovarian reserve
* refusal of the patient to consent for using her data in the study.

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: The improvement in inspiratory muscle function might result in beneficial changes in breathing pattern during whole body exercise. The hypothesis is the effect of inspiratory muscle training as an adjunct to a pulmonary rehabilitation program improves the breathing pattern during an incremental cycle exercise.


Options:
A: Inclusion Criteria:

* the individuals of the sample were required to have undergone Mechanical Ventilation for at least 48 hours in a controlled way
* intubation is diagnostic for acute respiratory injury type 1
* has a maximum value of MIP of -20 cmH2O16

Exclusion Criteria:

* any type of acute condition (cardiac arrhythmia) or chronic condition, such as insufficient congestive heart failure or unstable ischemic cardiac disease, that could compromise weaning or could impede the accomplishment of inspiratory muscle training (neuropathy and myopathy).
* Tracheostomized patients (in the pre-test).
* patients with neurological problems (cerebral vascular accident, cerebrospinal trauma or spinal medullar trauma.
* patients with morbid obesity
* patients taking medicine that could cause a disorder of attention.
* cases of auto-extubation.
B: Inclusion Criteria:

* Failure to wean patients in the medial, surgical and intermediate respiratory care units at Shands Hospital
* medically stable
* able to initiate spontaneous breaths
* able to provide informed consent
* able to follow simple instructions

Exclusion Criteria:

* life expectancy \< 12 months due to malignancy
* damaged phrenic nerves
* neuromuscular diseases
* heart or lung transplant
C: Inclusion Criteria:

* Patients with COPD stage 3 or 4
* Hospitalized in the pulmonary rehabilitation unit in the hospital of Morlaix, with a 3 weeks pulmonary rehabilitation course;

Exclusion Criteria:

* FEV ≥ 50%
* Pneumonectomy, Lobectomy less than 6 months
* Patient with risk of spontaneous pneumothorax or rib fracture
D: Inclusion Criteria:

* Clinically stable COPD patients
* maximal inspiratory pressure \<100% of the predicted normal value

Exclusion Criteria:

* Major comorbidities preventing successful participation in an 8 week exercise training intervention

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Efficacy and Impact of a Comprehensive Smoking Cessation Intervention During Radiation for Upper Aerodigestive Cancers
Brief Summary: Smoking is the greatest risk factor for upper aerodigestive cancers (thoracic or head and neck) and negatively impacts survival and other outcomes, but many patients have difficulty quitting after their diagnosis. Smoking cessation interventions for cancer patients thus far have had limited success. This is a pilot randomized controlled trial designed to determine if a new comprehensive, evidence-based smoking cessation intervention can improve quit rates for cancer patients who smoke.


Options:
A: Inclusion Criteria:

* Subjects must have smoked an average of at least 10 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year.

Exclusion Criteria:

* Subjects who have used bupropion, Zyban, or Wellbutrin previously.
B: Inclusion Criteria:

* New diagnosis of head and neck or thoracic (including lung) cancer
* Undergoing radiation at Johns Hopkins Radiation Oncology for 5 or more weeks
* English-speaking and able to provide informed consent
* Smoked any cigarettes in previous 14 days

Exclusion Criteria:

* Palliative radiation
* Undergoing stereotactic radiosurgery
* Pregnant or breastfeeding
C: Inclusion Criteria:

* Subjects must have smoked an average of at least ten cigarettes per day during the past year
* No period of abstinence greater than three months in the past year

Exclusion Criteria:

* Subjects with history of clinically significant cardiovascular disease
* Subjects with uncontrolled hypertension.
D: Inclusion Criteria:

* The sample, 40 women and 40 men, will be hospitalized patients recruited from Stanford Hospital and Clinics who report smoking at least 10 cigarettes per day prior to hospitalization, have confirmed tobacco use by cotinine testing, and an expected hospitalization of at least 3 days duration from the date of study enrollment. Intention to quit smoking will not be required for study participation.

Exclusion Criteria:

- Study exclusion criteria are: dementia or other brain injury precluding ability to participate; Alzheimer's Disease; Parkinson's Disease; Huntington's Disease; meningitis; seizure disorder of a sustained nature; delirium; brain surgery; drug and/or alcohol dependence; suicidal ideation; end-stage renal disease (i.e., on dialysis); hypertensive crisis; stroke; myocardial infarction (MI) with severe cardiac damage; pregnancy or breastfeeding; non-English speaking; complete homelessness; or currently engaged in tobacco treatment. Study staff will consult with clinical staff prior to approach for study enrollment. In cases of severe renal impairment (estimated creatinine clearance \<30 mL/min), medical staff will consult with participants' physician to assess the appropriateness for study enrollment.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Keeping Weight Off: Brain Changes Associated With Healthy Behaviors
Brief Summary: The goal of this project is to characterize changes in emotion regulation pathways associated with healthy behaviors in people who have recently lost weight and are seeking to maintain weight loss over a 1-year period.


Options:
A: Inclusion Criteria:

* Diabetes Type 2
* Albuminuria
* Age 30-70

Exclusion Criteria:

* Diabetes duration \< 3 years
* Preexisting non-diabetic kidney
* Psychiatric disorders
* Alcohol or drug abuse
* Malignant tumors or hematologic disorders
* Heart failure NYHA III-IV
* Acute coronary syndrome
B: Inclusion Criteria:

* Diabetes mellitus Type 1 or 2 for at least three months prior to inclusion
* Written informed consent
* Age ≥ 18 and ≤ 70
* Depressive symptoms as assessed by BDI-II score ≥ 14 (cut-off score indicating the presence of at least mild symptoms of depression)

Exclusion Criteria:

* Not being able to read and write Dutch
* Severe (psychiatric) co-morbidity
* Acute suicidal ideations or behavior
* Pregnancy
* Receiving an alternative psychological treatment during or less than two months prior to starting the participation in the study

Using an antidepressant drug during participation in the present study is allowed, on condition that a patient has been on stable medication regimen for at least two months prior to inclusion in the study, and that no new treatment with an antidepressant is initiated during the course of the study
C: Inclusion Criteria:

* 25 to 60 years old
* Healthy individuals who have intentionally lost at least 5% of their body weight over the past year
* BMI \>20.5 kg/m2 at study entry and \>25 in past 2 years

Exclusion Criteria:

* Weight-loss surgery or medications
* Serious Psychiatric or medical conditions
* Substance abuse
* Ineligible for MRI
* Pregnant
* Eating disorder
D: Inclusion Criteria:

* Age between 45-75 years
* Have overweight or obesity condition based in BMI (Body Mass Index). Individuals with BMI of 25 or more.
* Have two of these three risk: sedentary lifestyle, poor diet and binge episodes.
* Ability to understand oral and written Spanish.
* Willingness to participate in the study and signing informed consent.

Exclusion Criteria:

* Any diagnosis of a disease that may affect the central nervous system (brain condition, traumatic brain injury, dementia, etc).
* Other psychiatric diagnoses or acute psychiatric illness (substance dependence or abuse, history of schizophrenia or other psychotic disorders, etc.), except for anxiety disorder or personality disorders.
* Presence of delusional ideas or hallucinations whether consistent or not with mood.
* Suicide risk.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Botswana Vitamin D Supplementation Study in HIV/AIDS
Brief Summary: The goal is to determine the vit D supplementation dose that safely results in optimal serum vitamin D (25D) concentrations in HIV-infected children and adults living in Botswana. To do this the investigators will test two oral daily doses (4000 vs. 7000 IU) of cholecalciferol (D3) dietary supplement over a 12-week period in 60 children and adults with HIV/AIDS living in Botswana (5.0 to 50.9 yrs), to assess safety as determined by serum calcium and 25D concentrations and efficacy to replete vit D status as determined by achieving a minimum serum 25D concentration of 32 ng/mL (80 nmol/L).


Options:
A: Inclusion Criteria:

* Patients \> or = 21 years at enrollment
* Confirmed HIV positive with a CD4 range between 400 and 650 mm3
* HIV+ patients willing to participate in the study and who provide informed consent
* Pre-antiretroviral therapy (Pre-ART) at enrollment in study (not yet initiated ART)
* Willing to practice barrier method of birth control at all times

Exclusion Criteria:

* Patients intending to be transferred out of the clinic catchment area before study ends
* Patients scheduled to start ART
* Moribund patients
* Pregnant women
* Unable or not wanting to commit to barrier method of birth control
B: Inclusion Criteria:

* HIV infection
* Ages 5.0 to 50.9 y
* In usual state of good health
* Subject and/or family commitment to the 12-week study

Exclusion Criteria:

* Other chronic health conditions unrelated to HIV/AIDS that may affect nutritional status
* Use of vit D supplementation above 400 IU/d
C: Inclusion Criteria:

* HIV-infected children as defined by ≥ 2 positive HIV DNA PCRs and/or HIV cultures of blood for children less than 18 months of age, or by positive screening and confirmatory serologic testing in those older than 18 months of age
* Stable HIV disease, defined by the absence of change in HIV clinical or immunologic category during the preceding 6 month period, prior to commencing the study
* Age 3 years through 18 years
* Voluntary informed consent

Exclusion Criteria:

* Any antiretroviral medication change in the 6 months prior to the study, or any anticipated antiretroviral medication change during the duration of the study
* Active participation in another treatment trial
* Serum calcium \< 2mmol/L at baseline
D: Inclusion Criteria:

* Sputum-confirmed pulmonary tuberculosis
* Resident of Zomba or Blantyre Districts, Malawi
* Willing to take tuberculosis chemotherapy as recommended by the National Tuberculosis Control Programme

Exclusion Criteria:

* Prior treatment for tuberculosis

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Technology to Enhance Treatment for Early Conduct Problems in Low Income Families
Brief Summary: This study aims to the test the efficacy and cost effectiveness of new service delivery methods to enhance the reach and impact of the standard of care treatment, Behavioral Parent Training (BPT), for early onset disruptive behavior disorders.


Options:
A: Inclusion Criteria:

* Child aged 3 to 7 years
* has clinically significant disruptive behaviors
* low-income family

Exclusion Criteria:

* Caregiver has current mood, substance use, and/or psychotic disorder
* Child has current pervasive developmental and/or psychotic disorder
* Family has current allegation and/or past substantiation with child protective services
B: Inclusion Criteria:

* Child is 4 years old at time of recruitment
* Parent/guardian has access to a computer and the internet
* Parent/guardian is comfortable reading at a Grade 5 level
* Child meets screening criteria (SDQ score of 4 or more with some problems per impact score)

  * Child has had behavioural challenges for the last 6 months
  * Parent has access to phone in home
  * Parent speaks/writes Finnish

Exclusion Criteria:

* - Has received or is receiving behavioral treatment (parent training) before
* Diagnosis of:

  * Autism or a Pervasive development disorder (PDD)
  * Down's syndrome
  * Fetal Alcohol Syndrome
  * Mental retardation
  * Genetic diagnosis that will lead to mental retardation
  * Major mental health disorder (e.g., depression, psychosis)
* Child is not speaking using a sentence
* Child is deaf or blind
C: Inclusion Criteria:

* Pregnant women prior to the 25th week of gestation
* no previous live births
* one of the following sociodemographic risk characteristics:

  * young age (\< 19 years at registration);
  * unmarried
  * low socioeconomic status (Medicaid status or no private insurance)
D: Inclusion Criteria:

* Lower income
* caregiver/parent is legal guardian
* 3 to 8 year old child
* child meets criteria for externalizing disorder or significant externalizing symptoms

Exclusion Criteria:

* Prior report of child abuse or neglect
* current substance abuse/dependence
* legal guardian reading level less than 8th grade
* child has developmental disability that precludes caregiver utilizing the skills

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized Clinical Trial on Home Telemonitoring for the Management of Metabolic and Cardiovascular Risk in Individuals With Type 2 Diabetes
Brief Summary: The primary goal is to evaluate whether a home telehealth system that enables the participant to monitor their body weight, blood glucose values and blood pressure values, associated with remote educational support and feedback to the general practitioner, can improve metabolic control and overall cardiovascular risk in individuals with type 2 diabetes mellitus (T2DM), as compared to usual practice.


Options:
A: Inclusion Criteria:

* Diagnosis of type 2 Diabetes
* on SMBG al least 6 months before
* age superior of 30 years
* controlled in province of Málaga Primary Care Units

Exclusion Criteria:

* having diabetic complications or other diseases that could make difficult to use the telemedicine system
* patients who need a carer
* not passing the initial training (low cultural level)
* living in an area without mobile phone coverage
B: Inclusion Criteria:

* Age 70 years and older
* Diagnosis of type 1 or type 2 diabetes
* Seen at Joslin Clinic or Beth Israel Deaconess Medical Center for at least one year
* HbA1c 8% X 2 in past 6 months without fluctuation of more than 0.5% (i.e. stable poor control)
* No major change in medications in past 3 months, e.g. addition of insulin or another hypoglycemic agent

Exclusion Criteria:

* Patients with terminal diseases, e.g. malignancy with life expectancy of 12 months or less
* Patients who live more than 25 miles from Joslin Clinic/ Beth Israel Deaconess Medical Center
* Patients who live in an institutional setting, e.g. nursing home, group home, etc
* Patients who are not able to complete outcome assessments,(e.g. poor vision, diminished mental capacity/severe cognitive decline, unable to speak/read/write English, etc)
* Patients will be excluded from participation in Study Aim 3 if they have a history of orthostatic hypotension, TIA, or vertebral basilar insufficiency
C: Inclusion Criteria:

* has type 2 diabetes
* treated with oral agents in monotherapy or combined therapy ± basal insulin
* previously educated to self-monitoring blood glucose (SMBG) use

Exclusion Criteria:

* has type 2 diabetes non-pharmacologically treated
* has type 2 diabetes treated with multiple daily injections of insulin
* is unable to use the telemedicine system
* pregnancy
* has major cardiovascular, cerebrovascular, or peripheral vascular event in the last 6 months
* has any disease or condition, including alcohol or drugs abuse, that may interfere with study completion
D: Inclusion Criteria:

* diabetic, at least 18 years old, patient at a participating health clinic

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Observation of Treatment Patterns With Lucentis and Real Life Ophthalmic Monitoring, Including Optional OCT in Approved Indications
Brief Summary: A multicentre, open-label, non-interventional study to observe treatment patterns in patients with wet age-related macular degeneration (wAMD), with visual impairment due to diabetic macular edema (DME), due to macular edema following retinal vein occlusion (RVO) or due to chorioidal neovascularization following pathologic myopia (mCNV) with repeated intravitreal injections of Lucentis® (Ranibizumab) including optional OCT monitoring over a 24 months observational period under real life conditions.


Options:
A: Inclusion criteria:

* Presence of

  * neovascular (wet) age-related macular degeneration (AMD),
  * visual impairment due to diabetic macular oedema (DME),
  * visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) or
  * visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (PM)
* Patients for whom a therapy with Lucentis® is medically indicated.
* Written patients informed consent.

Exclusion criteria:

* As described in the SmPC.
* Preceding intravitreal treatment of the study eye with anti-VEGF drugs in the last three months before enrollment
* Preceding intravitreal treatment of the study eye with steroids
B: Inclusion Criteria:

* Diabetic macular edema with center involvement in at least one eye
* Type 1 or type 2 diabetes mellitus diagnosed 2 years prior to screening
* Laser photocoagulation in the study eye can be withheld for at least 3 months after randomization

Exclusion Criteria:

* Patients with uncontrolled systemic or ocular diseases
* Have any history of any intraocular surgery in the study eye within the past 6 months preceding screening
* Conditions that require chronic concomitant therapy with systemic or topical ocular corticosteroids

Other protocol-defined inclusion/exclusion criteria applied to the study.
C: Inclusion Criteria:

* macular edema associated with diabetes
* visual acuity between 20/50 and 20/200

Exclusion Criteria:

* recent laser therapy in the eye
* recent signs of uncontrolled diabetes
* blood pressure worse than 160/100
* severe cardiac disease
D: Inclusion Criteria:

* Visual acuity impairment
* Diabetic macular edema in at least one eye
* Type 1 or type 2 diabetes mellitus
* Medication for the diabetes treatment must be stable for the last 3 months

Exclusion Criteria:

* Patients with uncontrolled systemic or ocular diseases
* Laser photocoagulation in the study eye for the last 3 months
* Any history of any intraocular surgery in the study eye within the past 3 months
* Blood pressure \> 160/100 mmHg

Extension Inclusion Criteria:

-Completion of the Core Study

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Observation of Treatment Patterns With Lucentis and Real Life Ophthalmic Monitoring, Including Optional OCT in Approved Indications
Brief Summary: A multicentre, open-label, non-interventional study to observe treatment patterns in patients with wet age-related macular degeneration (wAMD), with visual impairment due to diabetic macular edema (DME), due to macular edema following retinal vein occlusion (RVO) or due to chorioidal neovascularization following pathologic myopia (mCNV) with repeated intravitreal injections of Lucentis® (Ranibizumab) including optional OCT monitoring over a 24 months observational period under real life conditions.


Options:
A: Inclusion Criteria:

* Cases with clinically significant macular edema (CSME) with persistent retinal thickening after initial or supplemental macular photocoagulation

Exclusion Criteria:

* Monocularity,
* History of vitrectomy,
* Glaucoma or ocular hypertension,
* Significant media opacity,
* Existence of traction on the macula
B: Inclusion Criteria:

* Center-involving Diabetic macular edema unresponsive to LASER therapy performed at least 3 moths prior to inclusion;
* Best corrected visual acuity equal or worse than 20/40 and better than 20/800;
* Central subfield macular thickness greater than 300 µm

Exclusion Criteria:

* Aphakia
* High-risk proliferative diabetic retinopathy
* Previous treatment for DME in the past three months
C: Inclusion: Persistent macular edema associated with diabetic retinopathy, uveitis, retinal vein occlusion, or Irvine-Gass syndrome, persisting at least 90 days after laser treatment or medical management by a physician.

Exclusion: Females who are pregnant or lactating, and females of childbearing potential not using adequate birth control for the duration of the study. Any intraocular procedures or laser treatment less than 90 days before enrollment.
D: Inclusion criteria:

* Presence of

  * neovascular (wet) age-related macular degeneration (AMD),
  * visual impairment due to diabetic macular oedema (DME),
  * visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) or
  * visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (PM)
* Patients for whom a therapy with Lucentis® is medically indicated.
* Written patients informed consent.

Exclusion criteria:

* As described in the SmPC.
* Preceding intravitreal treatment of the study eye with anti-VEGF drugs in the last three months before enrollment
* Preceding intravitreal treatment of the study eye with steroids

Answer: D